BG107717A - Метод за работа на компютърна система за извършване на цифров структурен анализ - Google Patents
Метод за работа на компютърна система за извършване на цифров структурен анализ Download PDFInfo
- Publication number
- BG107717A BG107717A BG107717A BG10771703A BG107717A BG 107717 A BG107717 A BG 107717A BG 107717 A BG107717 A BG 107717A BG 10771703 A BG10771703 A BG 10771703A BG 107717 A BG107717 A BG 107717A
- Authority
- BG
- Bulgaria
- Prior art keywords
- chemical
- molecules
- compounds
- fragment
- biological
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 245
- 238000004458 analytical method Methods 0.000 title claims description 43
- 239000000126 substance Substances 0.000 claims abstract description 380
- 239000012634 fragment Substances 0.000 claims abstract description 246
- 230000008569 process Effects 0.000 claims abstract description 97
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 39
- 238000012916 structural analysis Methods 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 311
- 230000000694 effects Effects 0.000 claims description 77
- 238000012360 testing method Methods 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 27
- 238000004364 calculation method Methods 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000003252 repetitive effect Effects 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000002110 toxicologic effect Effects 0.000 abstract description 13
- 231100000027 toxicology Toxicity 0.000 abstract description 9
- 230000002363 herbicidal effect Effects 0.000 abstract description 6
- 230000000361 pesticidal effect Effects 0.000 abstract description 5
- 238000007876 drug discovery Methods 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 238000000137 annealing Methods 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 description 109
- 102000005962 receptors Human genes 0.000 description 43
- 108020003175 receptors Proteins 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 41
- 230000027455 binding Effects 0.000 description 36
- 230000000875 corresponding effect Effects 0.000 description 36
- 239000003446 ligand Substances 0.000 description 34
- 230000004071 biological effect Effects 0.000 description 32
- 239000003112 inhibitor Substances 0.000 description 32
- 108091000080 Phosphotransferase Proteins 0.000 description 30
- 102000020233 phosphotransferase Human genes 0.000 description 30
- 238000004445 quantitative analysis Methods 0.000 description 29
- 238000011160 research Methods 0.000 description 27
- 238000012207 quantitative assay Methods 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000010586 diagram Methods 0.000 description 14
- -1 biological Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 11
- 239000004365 Protease Substances 0.000 description 11
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 11
- 230000008878 coupling Effects 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 108010016626 Dipeptides Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 9
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000015654 memory Effects 0.000 description 9
- 108091006146 Channels Proteins 0.000 description 8
- 229940043355 kinase inhibitor Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 7
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
- 108090000862 Ion Channels Proteins 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 239000000018 receptor agonist Substances 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 6
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
- 102000018674 Sodium Channels Human genes 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
- 229960000367 inositol Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000028828 purine nucleotide binding proteins Human genes 0.000 description 5
- 108091009376 purine nucleotide binding proteins Proteins 0.000 description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 108010085082 sigma receptors Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000481 chemical toxicant Toxicity 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004009 herbicide Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 229940121649 protein inhibitor Drugs 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 239000002213 purine nucleotide Substances 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 230000033458 reproduction Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 240000008881 Oenanthe javanica Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000003864 performance function Effects 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003982 sigma receptor ligand Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102400000988 Met-enkephalin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172814 Sodium channel protein Proteins 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 231100000777 Toxicophore Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002780 ion channel assay Methods 0.000 description 1
- 229940126181 ion channel inhibitor Drugs 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000413 phospholytic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000012732 spatial analysis Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/40—Searching chemical structures or physicochemical data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Computing Systems (AREA)
- Pharmacology & Pharmacy (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Complex Calculations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00309114 | 2000-10-17 | ||
| PCT/EP2001/011955 WO2002033596A2 (en) | 2000-10-17 | 2001-10-16 | Method of operating a computer system to perform a discrete substructural analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107717A true BG107717A (bg) | 2004-01-30 |
Family
ID=8173320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107717A BG107717A (bg) | 2000-10-17 | 2003-04-10 | Метод за работа на компютърна система за извършване на цифров структурен анализ |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040083060A1 (cs) |
| EP (1) | EP1366440A2 (cs) |
| JP (2) | JP2004512603A (cs) |
| KR (1) | KR20030059196A (cs) |
| CN (1) | CN1264110C (cs) |
| AU (2) | AU2002215028B2 (cs) |
| BG (1) | BG107717A (cs) |
| BR (1) | BR0114987A (cs) |
| CA (1) | CA2423672A1 (cs) |
| CZ (1) | CZ20031090A3 (cs) |
| EA (1) | EA005286B1 (cs) |
| EE (1) | EE200300150A (cs) |
| HR (1) | HRP20030240A2 (cs) |
| HU (1) | HUP0302507A3 (cs) |
| IL (1) | IL155332A0 (cs) |
| MX (1) | MXPA03003422A (cs) |
| NO (1) | NO20031730L (cs) |
| PL (1) | PL364772A1 (cs) |
| SK (1) | SK4682003A3 (cs) |
| UA (1) | UA79231C2 (cs) |
| WO (1) | WO2002033596A2 (cs) |
| YU (1) | YU25603A (cs) |
| ZA (1) | ZA200302395B (cs) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005069188A1 (ja) * | 2003-12-26 | 2005-07-28 | Dainippon Sumitomo Pharma Co., Ltd. | 化合物および蛋白質間の相互作用を予測するシステム |
| US20070260583A1 (en) * | 2004-03-05 | 2007-11-08 | Applied Research Systems Ars Holding N.V. | Method for fast substructure searching in non-enumerated chemical libraries |
| JP2006090733A (ja) * | 2004-09-21 | 2006-04-06 | Fuji Photo Film Co Ltd | 化合物抽出装置およびプログラム |
| EP1762954B1 (en) * | 2005-08-01 | 2019-08-21 | F.Hoffmann-La Roche Ag | Automated generation of multi-dimensional structure activity and structure property relationships |
| JP5512077B2 (ja) * | 2006-11-22 | 2014-06-04 | 株式会社 資生堂 | 安全性評価方法、安全性評価システム及び安全性評価プログラム |
| US20100205214A1 (en) * | 2008-12-05 | 2010-08-12 | Decript Inc. | Method for Creating Virtual Compound Libraries Within Markush Structure Patent Claims |
| CN102043864A (zh) * | 2010-12-30 | 2011-05-04 | 中山大学 | 中药心血管毒性分析的计算机操作方法及其系统 |
| WO2012139421A1 (zh) * | 2011-04-11 | 2012-10-18 | Yan Jingbo | 多维矩阵用于药物分子设计的应用及药物分子设计方法 |
| CN102262715B (zh) * | 2011-06-01 | 2013-09-11 | 山东大学 | Bcl-2蛋白抑制剂三维定量构效关系模型的构建方法及应用 |
| ES2392915B1 (es) * | 2011-06-03 | 2013-09-13 | Univ Sevilla | Compuestos bioactivos polifenolicos conteniendo azufre o selenio y sus usos |
| US9946847B2 (en) | 2012-09-22 | 2018-04-17 | Bioblocks Inc. | Libraries of compounds having desired properties and methods for making and using them |
| CN103049674A (zh) * | 2013-01-26 | 2013-04-17 | 北京东方灵盾科技有限公司 | 一种化学药物hERG钾离子通道阻断作用的定性预测方法及其系统 |
| US9799006B2 (en) | 2013-10-08 | 2017-10-24 | Baker Hughes Incorporated | Methods, systems and computer program products for chemical hazard evaluation |
| US9424517B2 (en) | 2013-10-08 | 2016-08-23 | Baker Hughes Incorporated | Methods, systems and computer program products for chemical hazard evaluation |
| US10975412B2 (en) | 2015-05-07 | 2021-04-13 | University Of Kentucky Research Foundation | Method for designing compounds and compositions useful for targeting high stoichiometric complexes to treat conditions, including treatment of viruses, bacteria, and cancers having acquired drug resistance |
| EP3206145A1 (en) * | 2016-02-09 | 2017-08-16 | InnovativeHealth Group SL | Method for producing a topical dermal formulation for cosmetic use |
| EP3646250A1 (en) * | 2017-05-30 | 2020-05-06 | GTN Ltd | Tensor network machine learning system |
| JP7317815B2 (ja) * | 2017-10-19 | 2023-07-31 | シュレーディンガー インコーポレイテッド | 代替コアを有する化合物の活性セットを予測する方法、およびそれを伴う創薬方法 |
| WO2020051714A1 (en) * | 2018-09-13 | 2020-03-19 | Cyclica Inc. | Method and system for predicting properties of chemical structures |
| EP3852113A4 (en) * | 2018-09-14 | 2021-10-27 | FUJIFILM Corporation | Method for assessing synthesis suitability of compound, program for assessing synthesis suitability of compound, and apparatus for assessing synthesis suitability of compound |
| US11580275B1 (en) * | 2018-12-18 | 2023-02-14 | X Development Llc | Experimental discovery processes |
| EP3712897A1 (en) * | 2019-03-22 | 2020-09-23 | Tata Consultancy Services Limited | Automated prediction of biological response of chemical compounds based on chemical information |
| CN110728078B (zh) * | 2019-11-14 | 2022-11-25 | 吉林大学 | 一种基于胶粘剂化学特性的粘接结构在全服役温度区间下的力学性能的预测方法 |
| CN111354424B (zh) * | 2020-02-27 | 2023-06-23 | 北京晶泰科技有限公司 | 一种潜在活性分子的预测方法、装置和计算设备 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6081766A (en) * | 1993-05-21 | 2000-06-27 | Axys Pharmaceuticals, Inc. | Machine-learning approach to modeling biological activity for molecular design and to modeling other characteristics |
| US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| WO2000049539A1 (en) * | 1999-02-19 | 2000-08-24 | Bioreason, Inc. | Method and system for artificial intelligence directed lead discovery through multi-domain clustering |
| WO2000079263A2 (en) * | 1999-06-18 | 2000-12-28 | Synt:Em S.A. | Identifying active molecules using physico-chemical parameters |
-
2001
- 2001-10-16 EP EP01983556A patent/EP1366440A2/en not_active Withdrawn
- 2001-10-16 YU YU25603A patent/YU25603A/sh unknown
- 2001-10-16 JP JP2002536914A patent/JP2004512603A/ja not_active Withdrawn
- 2001-10-16 HU HU0302507A patent/HUP0302507A3/hu unknown
- 2001-10-16 AU AU2002215028A patent/AU2002215028B2/en not_active Ceased
- 2001-10-16 BR BR0114987-3A patent/BR0114987A/pt not_active Application Discontinuation
- 2001-10-16 MX MXPA03003422A patent/MXPA03003422A/es active IP Right Grant
- 2001-10-16 CN CNB018207227A patent/CN1264110C/zh not_active Expired - Fee Related
- 2001-10-16 WO PCT/EP2001/011955 patent/WO2002033596A2/en not_active Ceased
- 2001-10-16 IL IL15533201A patent/IL155332A0/xx unknown
- 2001-10-16 AU AU1502802A patent/AU1502802A/xx active Pending
- 2001-10-16 EA EA200300475A patent/EA005286B1/ru not_active IP Right Cessation
- 2001-10-16 HR HR20030240A patent/HRP20030240A2/hr not_active Application Discontinuation
- 2001-10-16 ZA ZA200302395A patent/ZA200302395B/en unknown
- 2001-10-16 PL PL01364772A patent/PL364772A1/xx not_active Application Discontinuation
- 2001-10-16 KR KR10-2003-7005331A patent/KR20030059196A/ko not_active Ceased
- 2001-10-16 EE EEP200300150A patent/EE200300150A/xx unknown
- 2001-10-16 UA UA2003043420A patent/UA79231C2/uk unknown
- 2001-10-16 US US10/399,329 patent/US20040083060A1/en not_active Abandoned
- 2001-10-16 CA CA002423672A patent/CA2423672A1/en not_active Abandoned
- 2001-10-16 SK SK468-2003A patent/SK4682003A3/sk not_active Application Discontinuation
- 2001-10-16 CZ CZ20031090A patent/CZ20031090A3/cs unknown
-
2003
- 2003-04-10 BG BG107717A patent/BG107717A/bg unknown
- 2003-04-14 NO NO20031730A patent/NO20031730L/no not_active Application Discontinuation
-
2006
- 2006-12-04 JP JP2006327405A patent/JP2007137887A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA005286B1 (ru) | 2004-12-30 |
| BR0114987A (pt) | 2004-02-03 |
| PL364772A1 (en) | 2004-12-13 |
| SK4682003A3 (en) | 2003-12-02 |
| CA2423672A1 (en) | 2002-04-25 |
| HUP0302507A2 (hu) | 2003-11-28 |
| MXPA03003422A (es) | 2004-05-04 |
| HRP20030240A2 (en) | 2005-02-28 |
| IL155332A0 (en) | 2003-11-23 |
| US20040083060A1 (en) | 2004-04-29 |
| ZA200302395B (en) | 2004-03-29 |
| CZ20031090A3 (cs) | 2004-01-14 |
| HUP0302507A3 (en) | 2004-05-28 |
| UA79231C2 (en) | 2007-06-11 |
| EA200300475A1 (ru) | 2003-10-30 |
| NO20031730D0 (no) | 2003-04-14 |
| EE200300150A (et) | 2003-08-15 |
| CN1493051A (zh) | 2004-04-28 |
| HK1061911A1 (en) | 2004-10-08 |
| CN1264110C (zh) | 2006-07-12 |
| KR20030059196A (ko) | 2003-07-07 |
| WO2002033596A2 (en) | 2002-04-25 |
| JP2007137887A (ja) | 2007-06-07 |
| YU25603A (sh) | 2005-07-19 |
| AU2002215028B2 (en) | 2007-11-15 |
| EP1366440A2 (en) | 2003-12-03 |
| WO2002033596A3 (en) | 2003-10-02 |
| NO20031730L (no) | 2003-04-14 |
| JP2004512603A (ja) | 2004-04-22 |
| AU1502802A (en) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG107717A (bg) | Метод за работа на компютърна система за извършване на цифров структурен анализ | |
| Reker et al. | Active learning for computational chemogenomics | |
| Singh et al. | Feature selection of gene expression data for cancer classification: a review | |
| Boyle et al. | Expanding the olfactory code by in silico decoding of odor-receptor chemical space | |
| Schenone et al. | Target identification and mechanism of action in chemical biology and drug discovery | |
| AU2002215028A1 (en) | Method of operating a computer system to perform a discrete substructural analysis | |
| JP2009520278A (ja) | 科学情報知識管理のためのシステムおよび方法 | |
| CN110326051B (zh) | 用于识别生物样本中的表达区别要素的方法和分析系统 | |
| Pinzi et al. | Selection of protein conformations for structure-based polypharmacology studies | |
| Rollinger | Accessing target information by virtual parallel screening—the impact on natural product research | |
| Guruceaga et al. | Enhanced missing proteins detection in NCI60 cell lines using an integrative search engine approach | |
| Pascovici et al. | Combining protein ratio p-values as a pragmatic approach to the analysis of multirun iTRAQ experiments | |
| Feng et al. | Massive human co‐expression network and its medical applications | |
| US20030124548A1 (en) | Method for association of genomic and proteomic pathways associated with physiological or pathophysiological processes | |
| Vanderaa et al. | Utilizing Scp for the analysis and replication of single-cell proteomics data | |
| Watson et al. | Using multilayer heterogeneous networks to infer functions of phosphorylated sites | |
| Ugurlu | Machine Learning Applications in Drug Discovery | |
| WO2000065421A2 (en) | Receptor selectivity mapping | |
| Musso et al. | Experimental and computational procedures for the assessment of protein complexes on a genome-wide scale | |
| JP4298101B2 (ja) | 類似発現パターン抽出方法及び関連生体高分子抽出方法 | |
| Heffelfinger et al. | Carbon sequestration in Synechococcus Sp.: from molecular machines to hierarchical modeling | |
| Chen et al. | SMOPCA: spatially aware dimension reduction integrating multi-omics improves the efficiency of spatial domain detection | |
| Ruths et al. | De novo signaling pathway predictions based on protein-protein interaction, targeted therapy and protein microarray analysis | |
| Oduguwa et al. | An overview of soft computing techniques used in the drug discovery process | |
| van Beek | Channeling the data flood: handling large-scale biomolecular measurements in silico |